Literature DB >> 23541221

Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer.

Mohammad R Akbari1, Laura N Anderson, Daniel D Buchanan, Mark Clendenning, Mark A Jenkins, Aung Ko Win, John L Hopper, Graham G Giles, Robert Nam, Steven Narod, Steven Gallinger, Sean P Cleary.   

Abstract

INTRODUCTION: The HOXB13 pGly84Glu mutation has recently been associated with an increased risk of prostate cancer but the association of other cancer sites with this allele has not been assessed. Data has suggested that HOXB13 expression levels are decreased in colorectal cancer (CRC) cell lines indicating this gene may be involved in colorectal tumourigenesis.
METHODS: To evaluate a potential association of this mutation with CRC, we genotyped the mutation in 2695 CRC cases and 4593 controls from population-based registries in Canada and Australia.
RESULTS: The HOXB13 pGly84Glu mutation was more common in CRC cases than controls (0.48% vs. 0.17%, P=0.02) indicating a significant association between the HOXB13 variant and CRC risk (OR=2.8; 95%CI: 1.2-6.8). This association was attenuated but remained significant with the inclusion of previously published and publicly available genotype data. Pedigree analysis of cases and controls revealed that 7/21 HOXB13 mutation carriers had a family history of prostate cancer. DISCUSSION: This report is the first to suggest a risk of CRC associated with mutations in the HOXB13 gene. These findings require further validation but may be of importance in the screening and genetic counseling of families known to carry the HOXB13 pGly84Glu mutation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541221      PMCID: PMC3684005          DOI: 10.1016/j.canep.2013.03.003

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  13 in total

1.  Region-specific gastrointestinal Hox code during murine embryonal gut development.

Authors:  Yasuhiro Kawazoe; Tomohisa Sekimoto; Masatake Araki; Katsumasa Takagi; Kimi Araki; Ken-ichi Yamamura
Journal:  Dev Growth Differ       Date:  2002-02       Impact factor: 2.053

2.  Association between germline HOXB13 G84E mutation and risk of prostate cancer.

Authors:  Mohammad R Akbari; John Trachtenberg; Justin Lee; Stephanie Tam; Robert Bristow; Andrew Loblaw; Steven A Narod; Robert K Nam
Journal:  J Natl Cancer Inst       Date:  2012-07-09       Impact factor: 13.506

3.  Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.

Authors:  Joan P Breyer; T Grant Avritt; Kate M McReynolds; William D Dupont; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-19       Impact factor: 4.254

4.  Ontario familial colon cancer registry: methods and first-year response rates.

Authors:  M Cotterchio; G McKeown-Eyssen; H Sutherland; G Buchan; M Aronson; A M Easson; J Macey; E Holowaty; S Gallinger
Journal:  Chronic Dis Can       Date:  2000

5.  Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer.

Authors:  Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11-02       Impact factor: 4.254

6.  HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors.

Authors:  Kalpana Ghoshal; Tasneem Motiwala; Rainer Claus; Pearlly Yan; Huban Kutay; Jharna Datta; Sarmila Majumder; Shoumei Bai; Arnab Majumder; Tim Huang; Christoph Plass; Samson T Jacob
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.752

7.  The homeodomain protein HOXB13 regulates the cellular response to androgens.

Authors:  John D Norris; Ching-Yi Chang; Bryan M Wittmann; Rebecca S Kunder; Huaxia Cui; Daju Fan; James D Joseph; Donald P McDonnell
Journal:  Mol Cell       Date:  2009-11-13       Impact factor: 17.970

8.  Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals.

Authors:  Malcolm G Dunlop; Albert Tenesa; Susan M Farrington; Stephane Ballereau; David H Brewster; Thibaud Koessler; Paul Pharoah; Clemens Schafmayer; Jochen Hampe; Henry Völzke; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner; Susanna von Holst; Simone Picelli; Annika Lindblom; Mark A Jenkins; John L Hopper; Graham Casey; David Duggan; Polly A Newcomb; Anna Abulí; Xavier Bessa; Clara Ruiz-Ponte; Sergi Castellví-Bel; Iina Niittymäki; Sari Tuupanen; Auli Karhu; Lauri Aaltonen; Brent Zanke; Tom Hudson; Steven Gallinger; Ella Barclay; Lynn Martin; Maggie Gorman; Luis Carvajal-Carmona; Axel Walther; David Kerr; Steven Lubbe; Peter Broderick; Ian Chandler; Alan Pittman; Steven Penegar; Harry Campbell; Ian Tomlinson; Richard S Houlston
Journal:  Gut       Date:  2012-04-05       Impact factor: 23.059

9.  Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24.

Authors:  Brent W Zanke; Celia M T Greenwood; Jagadish Rangrej; Rafal Kustra; Albert Tenesa; Susan M Farrington; James Prendergast; Sylviane Olschwang; Theodore Chiang; Edgar Crowdy; Vincent Ferretti; Philippe Laflamme; Saravanan Sundararajan; Stéphanie Roumy; Jean-François Olivier; Frédérick Robidoux; Robert Sladek; Alexandre Montpetit; Peter Campbell; Stephane Bezieau; Anne Marie O'Shea; George Zogopoulos; Michelle Cotterchio; Polly Newcomb; John McLaughlin; Ban Younghusband; Roger Green; Jane Green; Mary E M Porteous; Harry Campbell; Helene Blanche; Mourad Sahbatou; Emmanuel Tubacher; Catherine Bonaiti-Pellié; Bruno Buecher; Elio Riboli; Sebastien Kury; Stephen J Chanock; John Potter; Gilles Thomas; Steven Gallinger; Thomas J Hudson; Malcolm G Dunlop
Journal:  Nat Genet       Date:  2007-07-08       Impact factor: 38.330

10.  HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation.

Authors:  C Jung; R-S Kim; H Zhang; S-J Lee; H Sheng; P J Loehrer; T A Gardner; M-H Jeng; C Kao
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

View more
  13 in total

1.  The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.

Authors:  Jennifer L Beebe-Dimmer; Matthew Hathcock; Cecilia Yee; Linda A Okoth; Charles M Ewing; William B Isaacs; Kathleen A Cooney; Stephen N Thibodeau
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-24       Impact factor: 4.254

2.  The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites.

Authors:  Lisa A Cannon-Albright; Jeff Stevens; Craig C Teerlink; Neeraj Agarwal
Journal:  Cancer Epidemiol       Date:  2020-10-21       Impact factor: 2.984

Review 3.  HOX genes: Major actors in resistance to selective endocrine response modifiers.

Authors:  Kideok Jin; Saraswati Sukumar
Journal:  Biochim Biophys Acta       Date:  2016-01-22

4.  Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort.

Authors:  Thomas J Hoffmann; Lori C Sakoda; Ling Shen; Eric Jorgenson; Laurel A Habel; Jinghua Liu; Mark N Kvale; Maryam M Asgari; Yambazi Banda; Douglas Corley; Lawrence H Kushi; Charles P Quesenberry; Catherine Schaefer; Stephen K Van Den Eeden; Neil Risch; John S Witte
Journal:  PLoS Genet       Date:  2015-01-28       Impact factor: 5.917

5.  HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.

Authors:  Cristina Villares Zabalza; Meike Adam; Christoph Burdelski; Waldemar Wilczak; Corina Wittmer; Stefan Kraft; Till Krech; Stefan Steurer; Christina Koop; Claudia Hube-Magg; Markus Graefen; Hans Heinzer; Sarah Minner; Ronald Simon; Guido Sauter; Thorsten Schlomm; Maria Christina Tsourlakis
Journal:  Oncotarget       Date:  2015-05-20

6.  Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.

Authors:  Sofia Maia; Marta Cardoso; Pedro Pinto; Manuela Pinheiro; Catarina Santos; Ana Peixoto; Maria José Bento; Jorge Oliveira; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  Germline HOXB13 p.Gly84Glu mutation and cancer susceptibility: a pooled analysis of 25 epidemiological studies with 145,257 participates.

Authors:  Qiliang Cai; Xinpeng Wang; Xiaodong Li; Rui Gong; Xuemei Guo; Yang Tang; Kuo Yang; Yuanjie Niu; Yan Zhao
Journal:  Oncotarget       Date:  2015-12-08

8.  HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions.

Authors:  Hannah Brechka; Raj R Bhanvadia; Calvin VanOpstall; Donald J Vander Griend
Journal:  Genes Dis       Date:  2017-02-16

Review 9.  Role of HOX Genes in Stem Cell Differentiation and Cancer.

Authors:  Seema Bhatlekar; Jeremy Z Fields; Bruce M Boman
Journal:  Stem Cells Int       Date:  2018-07-22       Impact factor: 5.443

10.  MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.

Authors:  Calvin VanOpstall; Srikanth Perike; Hannah Brechka; Marc Gillard; Sophia Lamperis; Baizhen Zhu; Ryan Brown; Raj Bhanvadia; Donald J Vander Griend
Journal:  Elife       Date:  2020-06-18       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.